Literature DB >> 31371567

Urodynamic study for distinguishing multiple system atrophy from Parkinson disease.

Jung Hyun Shin1, Kye Won Park1, Kyeong Ok Heo1, Sun Ju Chung1, Myung-Soo Choo2.   

Abstract

OBJECTIVE: To evaluate the differences in urodynamic findings between multiple system atrophy (MSA) and Parkinson disease (PD) and to identify the differential diagnostic ability of urodynamic study.
METHODS: We reviewed patients with MSA or PD who underwent urodynamic studies between January 2011 and August 2018. Patients with probable MSA and PD determined by movement disorder specialists at our center were included. Patients with alleged MSA or PD from outside hospitals, atypical or secondary parkinsonism, and any history of pelvic operation or radiation therapy were excluded.
RESULTS: A total of 219 patients, 107 with MSA (male:female 50:57) and 112 with PD (male:female 57:55), were included. Patients with MSA had shorter disease duration and were referred for urologic evaluation earlier (p < 0.001). Detrusor overactivity and associated urine leakage were prominent in PD (p < 0.001). Patients with MSA showed lower maximal flow rate (4.0 ± 5.8 vs 9.1 ± 8.3 mL/s, p < 0.001) and larger postvoid residual (290.8 ± 196.7 vs 134.0 ± 188.1 mL, p < 0.001) with decreased compliance (44.9% vs 10.7%, p < 0.001) and impaired contractility (24.9 ± 33.8 vs 65.7 ± 51.1, p < 0.001). Postvoid residual from a pressure-flow study had the highest sensitivity and specificity (74.8% and 75.9%), followed by detrusor pressure at maximal uroflow (72.6% and 70.5%), bladder contractility index, and postvoid residual from uroflowmetry (71.0% and 70.5%, respectively).
CONCLUSIONS: Patients with MSA showed lower maximal flow rate, larger postvoid residual with decreased compliance, and impaired contractility, whereas patients with PD had higher incidence of detrusor overactivity and associated leakage. For differential diagnosis, postvoid residual from a pressure-flow study provided the best sensitivity and specificity. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that urodynamic measures can distinguish patients with MSA from those with PD.
© 2019 American Academy of Neurology.

Entities:  

Year:  2019        PMID: 31371567     DOI: 10.1212/WNL.0000000000008053

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

Review 1.  Lower urinary tract dysfunction in Parkinsonian syndromes.

Authors:  Ekawat Vichayanrat; Claire Hentzen; Amit Batla; Sara Simeoni; Valeria Iodice; Jalesh N Panicker
Journal:  Neurol Sci       Date:  2021-07-28       Impact factor: 3.307

2.  Urodynamic Evaluation in Multiple System Atrophy: A Retrospective Cohort Study.

Authors:  Sabine Eschlböck; Gustav Kiss; Florian Krismer; Alessandra Fanciulli; Christine Kaindlstorfer; Cecilia Raccagni; Klaus Seppi; Stefan Kiechl; Jalesh N Panicker; Gregor K Wenning
Journal:  Mov Disord Clin Pract       Date:  2021-07-21

Review 3.  Cerebrospinal Fluid Metabolome in Parkinson's Disease and Multiple System Atrophy.

Authors:  Do Hyeon Kwon; Ji Su Hwang; Seok Gi Kim; Yong Eun Jang; Tae Hwan Shin; Gwang Lee
Journal:  Int J Mol Sci       Date:  2022-02-07       Impact factor: 5.923

4.  Effect of Deep Brain Stimulation on Female Parkinsonian Patients with Lower Urinary Tract Symptoms.

Authors:  Fuchao Liang; Yueqing Tang; Kaipeng Bi; Xuchen Liu; Chao Li; Si Chen; Chao Zhang; Lei Yan; Zhonghua Xu; Ning Yang
Journal:  Neuropsychiatr Dis Treat       Date:  2021-12-18       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.